Drugmaker AbbVie expects Humira volume erosion to worsen

AbbVie (ABBV.N) expects a drop in sales volumes of its blockbuster arthritis drug Humira to deepen after recent changes by U.S. pharmacy benefit managers and as patients shift to other drugs.